1.
Zhonghua Wai Ke Za Zhi
; 58(2): 99-104, 2020 Feb 01.
Artículo
en Chino
| MEDLINE
| ID: mdl-32074807
RESUMEN
Pancreatic cancer is malignant and has a poor prognosis.At present, the treatment mode has changed from "Surgery First" to systemic therapy under multi-disciplinary team, but surgical resection is still the only way to cure pancreatic cancer. In systemic treatment of pancreatic cancer, the effect of postoperative adjuvant therapy is significant, and preoperative neoadjuvant therapy has gradually attracted widespread attention. Neoadjuvant therapy can improve the rate of R0 resection in patients with pancreatic cancer.There is a consensus on neoadjuvant therapy for patients who with borderline resectable and locally advanced, but for the patients who with resectable remains controversial.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Terapia Neoadyuvante , Neoplasias Pancreáticas , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Consenso , Humanos , Estadificación de Neoplasias , Neoplasias Pancreáticas/tratamiento farmacológico
2.
Zhonghua Nei Ke Za Zhi
; 31(8): 484-9, 1992 Aug.
Artículo
en Chino
| MEDLINE
| ID: mdl-1304984